Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
56.77 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 434.249 | 363.329 | 351.406 | 271.03 | 103.714 | 51.495 | 2.612 | 0.133 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 45.209 | 28.32 | 16.008 | 6.129 | 9.008 | 1.146 | 0.001 | 183.204 | 1.384 | 0 | 0 | 0 | 0 |
| Gross Profit
| 389.04 | 335.009 | 335.398 | 264.901 | 94.706 | 50.349 | 2.611 | -183.071 | -1.384 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.896 | 0.922 | 0.954 | 0.977 | 0.913 | 0.978 | 1 | -1,376.474 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 648.449 | 705.789 | 497.153 | 412.084 | 357.355 | 293.998 | 231.644 | 183.204 | 114.737 | 45.967 | 27.829 | 12.641 | 4.717 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 127.724 | 99.909 | 64.936 | 33.001 | 10.811 | 4.451 | 3.344 | 1.844 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 309.799 | 278.139 | 219.982 | 182.933 | 161.524 | 127.724 | 99.909 | 64.936 | 33.001 | 10.811 | 4.451 | 3.344 | 1.844 |
| Other Expenses
| -0.337 | 9.508 | 0.241 | 7.645 | 12.451 | 3.954 | 10.604 | 2.168 | -0.2 | -3.024 | -3.006 | -0.35 | -0.022 |
| Operating Expenses
| 958.248 | 983.928 | 717.135 | 595.017 | 518.879 | 421.722 | 331.553 | 248.14 | 147.738 | 56.778 | 32.28 | 15.985 | 6.561 |
| Operating Income
| -569.208 | -648.919 | -381.737 | -330.116 | -424.173 | -371.373 | -328.942 | -248.007 | -147.738 | -56.778 | -32.28 | -15.985 | -6.561 |
| Operating Income Ratio
| -1.311 | -1.786 | -1.086 | -1.218 | -4.09 | -7.212 | -125.935 | -1,864.714 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -39.256 | -52.806 | -71.244 | 144.757 | 24.729 | 174.276 | 10.604 | 2.168 | -0.2 | -3.024 | -3.006 | -0.35 | -0.022 |
| Income Before Tax
| -608.464 | -701.725 | -452.981 | -185.359 | -399.444 | -197.097 | -318.338 | -245.839 | -145.618 | -59.802 | -35.07 | -16.334 | -6.849 |
| Income Before Tax Ratio
| -1.401 | -1.931 | -1.289 | -0.684 | -3.851 | -3.827 | -121.875 | -1,848.414 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -1.825 | 5.696 | 1.044 | 1.207 | 3.283 | 0.514 | -16.199 | 0.035 | -2.32 | -0.684 | -3.006 | -0.35 | 0.248 |
| Net Income
| -606.639 | -707.421 | -454.025 | -186.566 | -402.727 | -197.611 | -302.139 | -245.874 | -145.618 | -59.802 | -35.07 | -16.334 | -6.849 |
| Net Income Ratio
| -1.397 | -1.947 | -1.292 | -0.688 | -3.883 | -3.837 | -115.673 | -1,848.677 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -8.25 | -10.12 | -6.7 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.3 |
| EPS Diluted
| -8.25 | -10.12 | -6.7 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.3 |
| EBITDA
| -516.851 | -639.411 | -381.496 | -322.471 | -411.722 | -541.695 | -328.942 | -248.007 | -146.354 | -56.778 | -34.626 | -16.021 | -6.545 |
| EBITDA Ratio
| -1.19 | -1.76 | -1.086 | -1.19 | -3.97 | -10.519 | -125.935 | -1,864.714 | 0 | 0 | 0 | 0 | 0 |